Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim

The statistical dispute behind Lilly's withdrawal of its chronic pain sNDA for Cymbalta should come as no surprise to the sponsor - the issue was previewed during FDA's review of an earlier duloxetine indication, fibromyalgia

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet